Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

The Spectrum Strategic Income Fund

Bell Direct
November 6, 2018

The Schroder Fixed Income Fund

Bell Direct
November 6, 2018

The Schroder Absolute Return Income Fund

Bell Direct
November 6, 2018

Market Update

Julia Lee
September 21, 2018

Equity Investor 17 September

Julia Lee
September 18, 2018

Equity Investor 10 September

Julia Lee
September 11, 2018

Equity Investor 3 September

Julia Lee
September 4, 2018

Market Update

Julia Lee
August 31, 2018

Equity Investor 27 August

Julia Lee
August 28, 2018

Market Update

Julia Lee
August 27, 2018

Market Update

Julia Lee
August 24, 2018